Literature DB >> 6315450

Specific and potent interactions of carbamazepine with brain adenosine receptors.

P J Marangos, R M Post, J Patel, K Zander, A Parma, S Weiss.   

Abstract

Carbamazepine, a drug effective in pain, seizure, and affective disorders, was screened for its ability to interact with a variety of neurotransmitter and neuromodulator binding sites on brain membranes. The most potent effect was observed on adenosine antagonist ( [3H]DPX) binding to the adenosine receptor (KI = 3.5 +/- 0.4 microM) followed by adenosine agonist ( [3H]CHA) binding (KI = 24.5 +/- 3.6 microM). Lower potency effects were observed on benzodiazepine receptors, and no inhibition was seen in a variety of other systems. The inhibition of adenosine receptor binding by carbamazepine was competitive. No correlation was observed between the potency of a series of carbamazepine analogs as inhibitors of either ( [3H]DPX, [3H]CHA or [3H]diazepam binding and their ability to inhibit electroshock-induced convulsions, suggesting that the anticonvulsant properties of these agents are not mediated by the adenosine receptor, but raising the possibility that other clinical effects of carbamazepine may relate to its ability to act at the adenosine receptor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315450     DOI: 10.1016/0014-2999(83)90135-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Interaction of carbamazepine and other drugs with adenosine (A1 and A2) receptors.

Authors:  Y Fujiwara; M Sato; S Otsuki
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Effects of carbamazepine on dopamine function in rodents.

Authors:  M Elphick
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests.

Authors:  T Kuitunen; M J Mattila; T Seppälä; K Aranko; M E Mattila
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

4.  Mood stabilizer psychopharmacology.

Authors:  Todd D Gould; Guang Chen; Husseini K Manji
Journal:  Clin Neurosci Res       Date:  2002-11-14

5.  Adenosine inhibits epileptiform activity arising in hippocampal area CA3.

Authors:  B Ault; C M Wang
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

6.  Chronic carbamazepine down-regulates adenosine A2 receptors: studies with the putative selective adenosine antagonists PD115,199 and PD116,948.

Authors:  M Elphick; Z Taghavi; T Powell; P P Godfrey
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 7.  Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024.

Authors:  António F Ambrósio; Patrício Soares-Da-Silva; Caetana M Carvalho; Arsélio P Carvalho
Journal:  Neurochem Res       Date:  2002-02       Impact factor: 3.996

8.  Inhibition of agonist-stimulated inositol lipid metabolism by the anticonvulsant carbamazepine in rat hippocampus.

Authors:  E E McDermott; S D Logan
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

9.  Anxiolytic effect of carbamazepine in the elevated plus-maze: possible role of adenosine.

Authors:  H Zangrossi; J R Leite; F G Graeff
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Alterations in monoamine levels in discrete regions of rat brain after chronic administration of carbamazepine.

Authors:  M H Baf; M N Subhash; K M Lakshmana; B S Rao
Journal:  Neurochem Res       Date:  1994-09       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.